OS Therapies (NYSE:OSTX) Earns Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of OS Therapies (NYSE:OSTX) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $20.00 price objective on the stock.

Separately, Maxim Group lifted their price objective on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, January 16th.

OS Therapies Stock Down 10.1 %

Shares of OS Therapies stock opened at $1.70 on Thursday. The business has a fifty day simple moving average of $3.28 and a 200-day simple moving average of $3.13. OS Therapies has a 12 month low of $1.58 and a 12 month high of $7.00.

Insiders Place Their Bets

In other news, major shareholder Shalom Auerbach sold 100,000 shares of OS Therapies stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $2.84, for a total value of $284,000.00. Following the transaction, the insider now directly owns 2,431,211 shares in the company, valued at approximately $6,904,639.24. The trade was a 3.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Hedge Funds Weigh In On OS Therapies

A hedge fund recently raised its stake in OS Therapies stock. CM Management LLC boosted its position in shares of OS Therapies Inc (NYSE:OSTX) by 120.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 110,044 shares of the company’s stock after acquiring an additional 60,044 shares during the period. CM Management LLC owned approximately 0.51% of OS Therapies worth $471,000 at the end of the most recent quarter.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.